Kane Biotech Inc. (CVE:KNE – Get Free Report)’s stock price shot up 28.6% on Friday . The stock traded as high as C$0.05 and last traded at C$0.05. 1,505,028 shares were traded during trading, an increase of 380% from the average session volume of 313,629 shares. The stock had previously closed at C$0.04.
Kane Biotech Price Performance
The company has a current ratio of 0.80, a quick ratio of 0.39 and a debt-to-equity ratio of -331.42. The company has a 50 day moving average of C$0.04 and a 200-day moving average of C$0.04. The firm has a market capitalization of C$7.53 million, a P/E ratio of -0.56 and a beta of 0.60.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
See Also
- Five stocks we like better than Kane Biotech
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Do not delete, read immediately
- A month before the crash
- Claim Your Share of $5.39 BILLION in AI Equity Checks
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
